Effects of DPP‐4 inhibitor linagliptin and GLP‐1 receptor agonist liraglutide on physiological response to hypoglycaemia in Japanese subjects with type 2 diabetes: A randomized, open‐label, 2‐arm parallel comparative, exploratory trial

• Published in: Diabetes, obesity & metabolism Vol. 19; no. 3; pp. 442 - 447
• Main Authors: Yabe, Daisuke, Eto, Takashi, Shiramoto, Masanari, Irie, Shin, Murotani, Kenta, Seino, Yusuke, Kuwata, Hitoshi, Kurose, Takeshi, Seino, Susumu, Ahrén, Bo, Seino, Yutaka
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Publishing Ltd 01.03.2017; Wiley Subscription Services, Inc
• Subjects: Aged; Antidiabetics; Brief Report; Brief Reports; Clinical Medicine; Diabetes; Diabetes Mellitus, Type 2 - drug therapy; Dipeptidyl-peptidase IV; Dipeptidyl-Peptidase IV Inhibitors - therapeutic use; DPP-4 inhibitor; Endocrinology and Diabetes; Endokrinologi och diabetes; Epinephrine - metabolism; Evidence-based medicine; Female; GLP-1 receptor agonist; GLP-1 receptor agonists; Glucagon - metabolism; Glucagon response; Glucagon-Like Peptide-1 Receptor - agonists; Glucose; Glucose Clamp Technique; Human Growth Hormone - metabolism; Humans; Hydrocortisone - metabolism; Hypoglycaemia; Hypoglycemia; Hypoglycemia - metabolism; Hypoglycemic Agents - therapeutic use; Japan; Klinisk medicin; Linagliptin - therapeutic use; Liraglutide - therapeutic use; Male; Medical and Health Sciences; Medicin och hälsovetenskap; Middle Aged; Norepinephrine - metabolism; Sympatho-adrenal response; glucagon response; sympatho-adrenal response; GLP-1 receptor agonist; hypoglycaemia; DPP-4 inhibitor

Dipeptidyl peptidase‐4 (DPP‐4) inhibitors reduce the risk of hypoglycaemia, possibly through augmentation of glucose‐dependent insulinotropic polypeptide (GIP) action, but not that of glucagon‐like peptide‐1 (GLP‐1) on glucagon secretion. To examine this model in Japanese individuals with type 2 dia...